Memory Disorders
Conditions
Brief summary
The Inserm NeuroPresage team has been using MRI for more than 20 years in the study of normal ageing and memory pathologies to further the understanding and the characterization of early diagnosis and the cerebral substrates of cognitive deficits in patients, particularly in the context of neurodegenerative diseases. Two years ago, a new 3T MRI camera was installed at the Cyceron centre. It is more efficient and should make it possible to obtain better quality images and/or to reduce the time required to acquire these images. In this context, it seems important to test the different sequences that we classically use in our studies, or that we plan to implement in our next studies (learning and text retrieval fMRI task), in order to optimize them, with a view to integrating them in our future studies.
Interventions
OTHERMRI sequences testing
Testing different MRI sequences in order to optimize them
Sponsors
University Hospital, Caen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Healthy volunteers of legal age * Affiliation with a social security scheme or beneficiary of such a scheme * Signing of the protocol informed consent * For women of childbearing age or capacity, a urine pregnancy test before inclusion
Exclusion criteria
* Protected persons in accordance with articles L. 1121-5 to L.1121-8 of the Public Health Code: protected adults, pregnant and nursing women * Presence of contraindications to MRI examination without contrast agents injection * Presence of a chronic neurological or psychiatric condition (including substance use disorder) * History of brain disease (vascular, degenerative, malformative, tumour, or head trauma with loss of consciousness for more than one hour) * Current or recent use of medications that may interfere with imaging (psychotropic drugs, antihistamines with anticholinergic action, antiparkinsonian drugs, benzodiazepines including muscle relaxants, long-term steroidal anti-inflammatory drugs, antiepileptic drugs, central painkillers)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Optimization of MRI sequences | During MRI sessions | TR, TE, Flip Angle, asset phase, asset slice parameters |
Countries
France
Contacts
Primary ContactGéraldine Poisnel, PhD
Outcome results
None listed